Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
proton pump inhibitors, not dependent on acid activation	4993	881681-00-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vonoprazan vonoprazan fumarate takecab TAK-438	Vonoprazan is a potassium-competitive proton pump blocker which was approved in Japan for the treatment of gastroduodenal ulcer. FDA approved a co-packaged combination of vonoprazan and antibiotics (amoxicillin and clarithromycin) to eradicate Helicobacter pyroli. Its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 was investigated. Accordingly, it is recommended to use tocilizumabin combination with dexamethasone (or another corticosteroid at an equivalent dose) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19. Molecular weight: 345.39 Formula: C17H16FN3O2S CLOGP: 2.54 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 63.99 ALOGS: -3.85 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vonoprazan
vonoprazan fumarate
takecab
TAK-438

Vonoprazan is a potassium-competitive proton pump blocker which was approved in Japan for the treatment of gastroduodenal ulcer. FDA approved a co-packaged combination of vonoprazan and antibiotics (amoxicillin and clarithromycin) to eradicate Helicobacter pyroli. Its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 was investigated. Accordingly, it is recommended to use tocilizumabin combination with dexamethasone (or another corticosteroid at an equivalent dose) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19.

Molecular weight: 345.39
Formula: C17H16FN3O2S
CLOGP: 2.54
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 63.99
ALOGS: -3.85
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EGFR,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1	25
kinase-selectivity-class	AXL,BRAF,CDK9,EPHB4,ERBB2,GRK2,MAPK7,SIK2	8
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 2014	PMDA
Nov. 1, 2023	FDA	PHATHOM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	175.91	22.02	80	6628	46208	90575531
Renal impairment	105.15	22.02	76	6632	105345	90516394
Interstitial lung disease	94.77	22.02	63	6645	76342	90545397
Platelet count decreased	91.64	22.02	78	6630	136891	90484848
Cerebral infarction	85.57	22.02	41	6667	26555	90595184
Cardiac failure	74.53	22.02	63	6645	109433	90512306
Decreased appetite	73.60	22.02	113	6595	376427	90245312
Anaemia	70.52	22.02	107	6601	352695	90269044
Neutrophil count decreased	63.25	22.02	48	6660	71484	90550255
Gastric polyps	57.49	22.02	19	6689	4653	90617086
Fulminant type 1 diabetes mellitus	55.96	22.02	13	6695	865	90620874
Drug eruption	50.76	22.02	32	6676	35375	90586364
Enterocolitis	49.06	22.02	21	6687	10469	90611270
Pneumonia bacterial	48.19	22.02	22	6686	12768	90608971
Altered state of consciousness	46.46	22.02	29	6679	31503	90590236
White blood cell count decreased	45.71	22.02	59	6649	167050	90454689
Gastric cancer	40.53	22.02	15	6693	5121	90616618
Disseminated intravascular coagulation	40.02	22.02	23	6685	21515	90600224
Hypergastrinaemia	38.57	22.02	7	6701	134	90621605
Cytokine release syndrome	36.91	22.02	24	6684	27949	90593790
Aplasia pure red cell	36.73	22.02	14	6694	5180	90616559
Gastrointestinal polyp haemorrhage	36.22	22.02	8	6700	424	90621315
Marasmus	36.03	22.02	9	6699	814	90620925
Pneumonia aspiration	35.13	22.02	27	6681	40913	90580826
Pulmonary toxicity	34.73	22.02	17	6691	11514	90610225
Cardiac failure acute	34.18	22.02	17	6691	11912	90609827
Fatigue	33.88	22.02	22	6686	1154001	89467738
Enterocolitis haemorrhagic	33.70	22.02	10	6698	1722	90620017
Cardiac failure chronic	32.12	22.02	13	6695	5633	90616106
Focal peritonitis	31.58	22.02	5	6703	40	90621699
Blood pressure decreased	31.47	22.02	33	6675	74862	90546877
Pneumocystis jirovecii pneumonia	29.64	22.02	19	6689	21597	90600142
Dehydration	29.30	22.02	52	6656	194395	90427344
Pyrexia	29.20	22.02	111	6597	660374	89961365
Hypocalcaemia	28.01	22.02	24	6684	42344	90579395
Pain	27.87	22.02	20	6688	996321	89625418
Diabetic ketoacidosis	27.54	22.02	19	6689	24388	90597351
Hypomagnesaemia	27.36	22.02	22	6686	35566	90586173
Liver disorder	27.34	22.02	39	6669	121230	90500509
Aortic dissection	26.45	22.02	9	6699	2408	90619331
Erythema multiforme	25.24	22.02	14	6694	12232	90609507
Hypothyroidism	25.21	22.02	25	6683	53102	90568637
Herpes zoster	25.20	22.02	33	6675	94611	90527128
Drug-induced liver injury	24.84	22.02	32	6676	90286	90531453
Hypoalbuminaemia	24.37	22.02	15	6693	15882	90605857
COVID-19	23.95	22.02	44	6664	168799	90452940
Cholangitis	22.87	22.02	11	6697	7171	90614568
Familial mediterranean fever	22.60	22.02	4	6704	66	90621673
Femur fracture	22.45	22.02	22	6686	46060	90575679
Nephrogenic anaemia	22.43	22.02	8	6700	2458	90619281

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	234.06	19.86	160	8043	78302	42534830
Hepatic function abnormal	99.29	19.86	81	8122	51486	42561646
Immune-mediated enterocolitis	84.04	19.86	34	8169	5643	42607489
Cerebral infarction	82.04	19.86	59	8144	31110	42582022
Pulmonary toxicity	67.27	19.86	33	8170	8622	42604510
Decreased appetite	66.71	19.86	127	8076	193010	42420122
Renal impairment	65.98	19.86	93	8110	110135	42502997
Cardiac failure	63.72	19.86	90	8113	106766	42506366
Pneumonia aspiration	61.35	19.86	61	8142	50017	42563115
Cholangitis	57.83	19.86	32	8171	10695	42602437
Immune-mediated hepatic disorder	54.94	19.86	20	8183	2494	42610638
Adrenal insufficiency	54.83	19.86	38	8165	18886	42594246
Pneumonia bacterial	53.83	19.86	35	8168	15657	42597475
Liver disorder	53.63	19.86	51	8152	39593	42573539
Colitis microscopic	47.18	19.86	19	8184	3114	42610018
Hypergastrinaemia	44.43	19.86	10	8193	216	42612916
Neutrophil count decreased	40.12	19.86	55	8148	63360	42549772
Gastric cancer	38.32	19.86	21	8182	6882	42606250
Adrenocorticotropic hormone deficiency	37.95	19.86	13	8190	1357	42611775
Cholangitis acute	35.87	19.86	12	8191	1165	42611967
Immune-mediated lung disease	35.49	19.86	16	8187	3457	42609675
Blood gastrin increased	33.39	19.86	6	8197	38	42613094
Asthenia	32.87	19.86	7	8196	280786	42332346
Malignant neoplasm progression	32.16	19.86	67	8136	108333	42504799
Radiation pneumonitis	31.53	19.86	14	8189	2919	42610213
Cytokine release syndrome	30.26	19.86	40	8163	44487	42568645
Cholangitis sclerosing	30.25	19.86	12	8191	1890	42611242
Drug-induced liver injury	30.14	19.86	37	8166	38236	42574896
Disseminated intravascular coagulation	29.96	19.86	30	8173	24764	42588368
Tumour haemorrhage	28.65	19.86	14	8189	3624	42609508
Non-small cell lung cancer	27.25	19.86	15	8188	4959	42608173
C-reactive protein increased	27.23	19.86	46	8157	63514	42549618
Immune-mediated cholangitis	27.02	19.86	8	8195	521	42612611
Fulminant type 1 diabetes mellitus	26.60	19.86	10	8193	1364	42611768
Enterocolitis	26.57	19.86	19	8184	9910	42603222
Altered state of consciousness	25.85	19.86	30	8173	29229	42583903
Drug eruption	24.42	19.86	26	8177	23049	42590083
Platelet count decreased	24.33	19.86	70	8133	138511	42474621
Physical deconditioning	24.32	19.86	11	8192	2394	42610738
Drug ineffective	23.06	19.86	55	8148	630142	41982990
Marasmus	22.85	19.86	8	8195	891	42612241
Renal disorder	22.79	19.86	28	8175	28952	42584180
Hepatocellular carcinoma	22.66	19.86	16	8187	8178	42604954
Immune-mediated hepatitis	22.39	19.86	12	8191	3762	42609370
Pleural effusion	22.04	19.86	54	8149	97112	42516020
Dyslalia	21.46	19.86	7	8196	628	42612504
Cardiac failure acute	21.26	19.86	19	8184	13614	42599518
Thyroiditis	21.22	19.86	11	8192	3225	42609907
Thrombophlebitis migrans	20.68	19.86	6	8197	364	42612768
Fatigue	20.23	19.86	33	8170	435608	42177524

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	327.46	19.20	215	14824	139119	110435141
Hepatic function abnormal	262.83	19.20	159	14880	89136	110485124
Renal impairment	162.97	19.20	162	14877	188283	110385977
Cerebral infarction	162.01	19.20	96	14943	51742	110522518
Cardiac failure	132.92	19.20	145	14894	187481	110386779
Decreased appetite	127.30	19.20	230	14809	475616	110098644
Pulmonary toxicity	104.04	19.20	50	14989	17696	110556564
Platelet count decreased	102.79	19.20	141	14898	230302	110343958
Pneumonia bacterial	101.80	19.20	56	14983	26205	110548055
Pneumonia aspiration	101.72	19.20	86	14953	81147	110493113
Neutrophil count decreased	100.83	19.20	102	14937	120839	110453421
Immune-mediated enterocolitis	99.34	19.20	41	14998	10144	110564116
Cholangitis	86.69	19.20	43	14996	16292	110557968
Immune-mediated hepatic disorder	72.40	19.20	26	15013	4424	110569836
Enterocolitis	72.32	19.20	40	14999	18909	110555351
Hypergastrinaemia	71.10	19.20	15	15024	341	110573919
Drug eruption	69.62	19.20	58	14981	53601	110520659
Altered state of consciousness	68.03	19.20	59	14980	57567	110516693
Cytokine release syndrome	67.34	19.20	64	14975	70242	110504018
Disseminated intravascular coagulation	67.21	19.20	51	14988	41235	110533025
Fulminant type 1 diabetes mellitus	67.11	19.20	21	15018	2342	110571918
Gastric cancer	64.47	19.20	31	15008	10977	110563283
Liver disorder	63.31	19.20	87	14952	142156	110432104
Anaemia	62.99	19.20	190	14849	546896	110027364
Malignant neoplasm progression	60.65	19.20	95	14944	174472	110399788
Fatigue	59.70	19.20	47	14992	1215911	109358349
Adrenal insufficiency	59.56	19.20	48	14991	42342	110531918
Pain	57.73	19.20	29	15010	954926	109619334
Gastric polyps	56.47	19.20	23	15016	5500	110568760
Colitis microscopic	53.11	19.20	29	15010	13365	110560895
White blood cell count decreased	52.60	19.20	104	14935	229286	110344974
Marasmus	52.12	19.20	16	15023	1675	110572585
Cardiac failure acute	48.87	19.20	34	15005	24044	110550216
Radiation pneumonitis	46.75	19.20	19	15020	4517	110569743
Blood gastrin increased	46.35	19.20	8	15031	58	110574202
Joint swelling	45.48	19.20	4	15035	442841	110131419
Blood pressure decreased	44.72	19.20	66	14973	115025	110459235
Asthenia	44.57	19.20	19	15020	688980	109885280
Drug hypersensitivity	44.29	19.20	5	15034	454085	110120175
Adrenocorticotropic hormone deficiency	44.15	19.20	15	15024	2167	110572093
Physical deconditioning	44.10	19.20	17	15022	3520	110570740
Drug-induced liver injury	44.01	19.20	67	14972	120000	110454260
Immune-mediated lung disease	43.89	19.20	19	15020	5284	110568976
Drug ineffective	43.22	19.20	89	14950	1520451	109053809
Hypothyroidism	42.50	19.20	51	14988	72848	110501412
Aplasia pure red cell	41.51	19.20	22	15017	9556	110564704
Peripheral swelling	40.55	19.20	4	15035	404030	110170230
Gastrointestinal polyp haemorrhage	40.10	19.20	11	15028	774	110573486
Cardiac failure chronic	39.04	19.20	24	15015	13787	110560473
Immune-mediated cholangitis	38.80	19.20	11	15028	873	110573387
Pyrexia	38.73	19.20	231	14808	898034	109676226
Cholangitis acute	38.11	19.20	13	15026	1900	110572360
Tumour haemorrhage	37.63	19.20	17	15022	5228	110569032
Pneumocystis jirovecii pneumonia	37.33	19.20	37	15002	42698	110531562
Non-small cell lung cancer	36.59	19.20	19	15020	7916	110566344
COVID-19	35.89	19.20	93	14946	244967	110329293
Febrile neutropenia	35.41	19.20	109	14930	316658	110257602
Hypoalbuminaemia	34.86	19.20	30	15009	28944	110545316
Hypomagnesaemia	34.81	19.20	42	14997	60328	110513932
Enterocolitis haemorrhagic	34.20	19.20	13	15026	2591	110571669
Swelling	33.88	19.20	4	15035	351037	110223223
Pleural effusion	33.06	19.20	74	14965	177635	110396625
Hepatocellular carcinoma	32.69	19.20	19	15020	9861	110564399
Dehydration	32.00	19.20	97	14942	279414	110294846
Melaena	32.00	19.20	43	14996	68714	110505546
Anxiety	30.79	19.20	5	15034	345073	110229187
Ascites	30.13	19.20	49	14990	92759	110481501
Erythema multiforme	29.86	19.20	24	15015	21073	110553187
Aortic dissection	29.21	19.20	14	15025	4919	110569341
KL-6 increased	28.67	19.20	7	15032	310	110573950
Vanishing bile duct syndrome	28.36	19.20	12	15027	3156	110571104
Focal peritonitis	28.11	19.20	5	15034	44	110574216
Immune-mediated hepatitis	27.91	19.20	15	15024	6696	110567564
Hypopituitarism	27.65	19.20	13	15026	4377	110569883
Rheumatoid arthritis	27.51	19.20	4	15035	299609	110274651
Oesophageal candidiasis	27.50	19.20	18	15021	11516	110562744
Immune-mediated myocarditis	27.22	19.20	12	15027	3486	110570774
Paraesthesia	27.06	19.20	3	15036	276518	110297742
Cholangitis sclerosing	26.94	19.20	12	15027	3570	110570690
Nephrotic syndrome	26.83	19.20	19	15020	13812	110560448
Gastrointestinal perforation	26.43	19.20	15	15024	7441	110566819
Bile duct stone	26.00	19.20	14	15025	6275	110567985
Diabetic ketoacidosis	25.46	19.20	30	15009	42028	110532232
Thyroiditis	25.42	19.20	14	15025	6559	110567701
Musculoskeletal stiffness	25.08	19.20	4	15035	279818	110294442
Hypersensitivity	24.75	19.20	12	15027	403986	110170274
Cerebellar haemorrhage	24.74	19.20	11	15028	3260	110571000
Hypocalcaemia	24.68	19.20	37	15002	65329	110508931
Renal disorder	24.65	19.20	32	15007	49447	110524813
Systemic lupus erythematosus	24.29	19.20	3	15036	254335	110319925
Spinal compression fracture	24.09	19.20	20	15019	18372	110555888
Organising pneumonia	24.07	19.20	18	15021	14225	110560035
Shunt occlusion	24.00	19.20	9	15030	1728	110572532
Hepatic encephalopathy	23.82	19.20	24	15015	28232	110546028
Type 1 diabetes mellitus	23.75	19.20	15	15024	9032	110565228
Pain in extremity	23.59	19.20	19	15020	487099	110087161
Hyperkalaemia	23.54	19.20	55	14984	135741	110438519
Gastric ulcer	23.43	19.20	28	15011	39799	110534461
Compression fracture	23.37	19.20	15	15024	9284	110564976
Immune-mediated gastritis	23.28	19.20	6	15033	332	110573928
Gastric mucosal hypertrophy	23.26	19.20	6	15033	333	110573927
Sinusitis	22.95	19.20	6	15033	296682	110277578
Diarrhoea	22.93	19.20	246	14793	1139259	109435001
Thrombophlebitis migrans	22.49	19.20	7	15032	767	110573493
Dyslalia	22.11	19.20	8	15031	1389	110572871
Dyspnoea	22.09	19.20	77	14962	1106795	109467465
Alopecia	22.09	19.20	11	15028	364742	110209518
Maternal exposure during pregnancy	22.06	19.20	4	15035	254879	110319381
Pneumonia	21.87	19.20	198	14841	876516	109697744
Cholecystitis	21.85	19.20	22	15017	25860	110548400
Blood corticotrophin decreased	21.84	19.20	7	15032	843	110573417
Toxicity to various agents	21.74	19.20	20	15019	480535	110093725
COVID-19 pneumonia	21.67	19.20	26	15013	37117	110537143
Femoral neck fracture	21.50	19.20	16	15023	12551	110561709
Underdose	21.23	19.20	34	15005	63520	110510740
Small intestinal haemorrhage	21.13	19.20	11	15028	4607	110569653
Lymphangiosis carcinomatosa	20.89	19.20	9	15030	2473	110571787
Therapeutic product effect decreased	20.79	19.20	4	15035	244312	110329948
Condition aggravated	20.78	19.20	43	14996	734793	109839467
Meningitis	20.25	19.20	15	15024	11687	110562573
Septic shock	20.25	19.20	57	14982	157471	110416789
Wheezing	20.05	19.20	5	15034	255225	110319035
Oesophagitis	19.95	19.20	22	15017	28693	110545567
Steroid diabetes	19.79	19.20	11	15028	5243	110569017
Large intestine perforation	19.56	19.20	17	15022	16612	110557648
Gastric antral vascular ectasia	19.49	19.20	7	15032	1190	110573070
Discomfort	19.39	19.20	3	15036	214704	110359556

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BC08	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors
ATC	A02BD14	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
ATC	A02BD15	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
ATC	A02BD17	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:49201	anti-ulcer drug

Related Drugs by ATC class:

A02BC Proton pump inhibitors 8 drugs

dexlansoprazole dexrabeprazole esomeprazole ilaprazole lansoprazole omeprazole pantoprazole rabeprazole

A02BD Combinations for eradication of Helicobacter pylori 13 drugs

amoxicillin bismuth subcitrate clarithromycin esomeprazole lansoprazole levofloxacin metronidazole omeprazole pantoprazole rabeprazole rifabutin tetracycline show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Erosive esophagitis	indication	40719004
Duodenal ulcer disease	indication	51868009	DOID:1724
Gastro-esophageal reflux disease with esophagitis	indication	266433003
Gastric ulcer	indication	397825006	DOID:10808
Infection caused by Helicobacter pylori	indication	721730009
Rilpivirine-containing products	contraindication	703123005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.09	Basic
pKa2	2.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	Nov. 1, 2026	NEW PRODUCT
EQ 20MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	Nov. 1, 2026	NEW PRODUCT
EQ 10MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	May 3, 2027	NEW CHEMICAL ENTITY
EQ 20MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	May 3, 2027	NEW CHEMICAL ENTITY
500MG;500MG;EQ 20MG BASE	VOQUEZNA TRIPLE PAK	PHATHOM	N215152	May 3, 2022	RX	CAPSULE, TABLET, TABLET	ORAL	May 3, 2027	NEW CHEMICAL ENTITY
500MG;EQ 20MG BASE	VOQUEZNA DUAL PAK	PHATHOM	N215153	May 3, 2022	RX	CAPSULE, TABLET	ORAL	May 3, 2027	NEW CHEMICAL ENTITY
EQ 10MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	July 17, 2027	USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS
EQ 10MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	May 3, 2032	GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 20MG BASE	VOQUEZNA	PHATHOM	N215151	Nov. 1, 2023	RX	TABLET	ORAL	May 3, 2032	GENERATING ANTIBIOTIC INCENTIVES NOW
500MG;500MG;EQ 20MG BASE	VOQUEZNA TRIPLE PAK	PHATHOM	N215152	May 3, 2022	RX	CAPSULE, TABLET, TABLET	ORAL	May 3, 2032	GENERATING ANTIBIOTIC INCENTIVES NOW
500MG;EQ 20MG BASE	VOQUEZNA DUAL PAK	PHATHOM	N215153	May 3, 2022	RX	CAPSULE, TABLET	ORAL	May 3, 2032	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Potassium-transporting ATPase	Transporter	P20648 P51164	ATP4A_HUMAN ATP4B_HUMAN	INHIBITOR	Ki	8		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
1R5L3J156G	UNII
D10466	KEGG_DRUG
881681-01-2	SECONDARY_CAS_RN
4041456	VANDF
C4080009	UMLSCUI
CHEBI:136048	CHEBI
HKT	PDB_CHEM_ID
CHEMBL2079130	ChEMBL_ID
15981397	PUBCHEM_CID
DB11739	DRUGBANK_ID
CHEMBL2064032	ChEMBL_ID
9535	INN_ID
C552956	MESH_SUPPLEMENTAL_RECORD_UI
11549	IUPHAR_LIGAND_ID
2604576	RXNORM
40597	MMSL
40790	MMSL
d09874	MMSL
019050	NDDF
019051	NDDF
555661000221100	SNOMEDCT_US
555671000221109	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VOQUEZNA	HUMAN PRESCRIPTION DRUG LABEL	1	81520-100	TABLET	13.36 mg	ORAL	NDA	32 sections
VOQUEZNA	HUMAN PRESCRIPTION DRUG LABEL	1	81520-200	TABLET	26.72 mg	ORAL	NDA	32 sections

Ask DrugCentral

vonoprazan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: